147 related articles for article (PubMed ID: 14555655)
21. HLA-B27 structure, function, and disease association.
López-Larrea C; Gonzalez-Roces S; Alvarez V
Curr Opin Rheumatol; 1996 Jul; 8(4):296-308. PubMed ID: 8864580
[TBL] [Abstract][Full Text] [Related]
22. Natural MHC class I polymorphism controls the pathway of peptide dissociation from HLA-B27 complexes.
Winkler K; Winter A; Rueckert C; Uchanska-Ziegler B; Alexiev U
Biophys J; 2007 Oct; 93(8):2743-55. PubMed ID: 17573425
[TBL] [Abstract][Full Text] [Related]
23. The peptide repertoires of HLA-B27 subtypes differentially associated to spondyloarthropathy (B*2704 and B*2706) differ by specific changes at three anchor positions.
Sesma L; Montserrat V; Lamas JR; Marina A; Vázquez J; López de Castro JA
J Biol Chem; 2002 May; 277(19):16744-9. PubMed ID: 11875071
[TBL] [Abstract][Full Text] [Related]
24. Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants. Implications for susceptibility to spondylarthropathies.
Boisgérault F; Tieng V; Stolzenberg MC; Dulphy N; Khalil I; Tamouza R; Charron D; Toubert A
J Clin Invest; 1996 Dec; 98(12):2764-70. PubMed ID: 8981922
[TBL] [Abstract][Full Text] [Related]
25. The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC.
Madden DR; Gorga JC; Strominger JL; Wiley DC
Cell; 1992 Sep; 70(6):1035-48. PubMed ID: 1525820
[TBL] [Abstract][Full Text] [Related]
26. Comparison of amino acid compositions of peptides eluted from HLA-B27 molecules of healthy individuals and patients with ankylosing spondylitis.
Stodůlková E; Pohl J; Man P; Votruba J; Capková J; Sedlácková M; Ivasková E; Ivanyi P; Flieger M
Immunol Lett; 2006 Mar; 103(2):135-41. PubMed ID: 16313971
[TBL] [Abstract][Full Text] [Related]
27. Structural basis for T cell alloreactivity among three HLA-B14 and HLA-B27 antigens.
Kumar P; Vahedi-Faridi A; Saenger W; Merino E; López de Castro JA; Uchanska-Ziegler B; Ziegler A
J Biol Chem; 2009 Oct; 284(43):29784-97. PubMed ID: 19617632
[TBL] [Abstract][Full Text] [Related]
28. Molecular mimicry: any role in the pathogenesis of spondyloarthropathies?
Lahesmaa R; Skurnik M; Toivanen P
Immunol Res; 1993; 12(2):193-208. PubMed ID: 7504716
[TBL] [Abstract][Full Text] [Related]
29. [Subtypes of the HLA-B27 molecule and association with spondylarthropathies].
Toubert A; Tieng V; Boisgérault F; Dulphy N; Tamouza R; Charron D
Ann Med Interne (Paris); 1998 Apr; 149(3):145-8. PubMed ID: 11490536
[TBL] [Abstract][Full Text] [Related]
30. Allele-dependent similarity between viral and self-peptide presentation by HLA-B27 subtypes.
Fiorillo MT; Rückert C; Hülsmeyer M; Sorrentino R; Saenger W; Ziegler A; Uchanska-Ziegler B
J Biol Chem; 2005 Jan; 280(4):2962-71. PubMed ID: 15537660
[TBL] [Abstract][Full Text] [Related]
31. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation.
Madden DR; Gorga JC; Strominger JL; Wiley DC
Nature; 1991 Sep; 353(6342):321-5. PubMed ID: 1922337
[TBL] [Abstract][Full Text] [Related]
32. Covalent HLA-B27/peptide complex induced by specific recognition of an aziridine mimic of arginine.
Weiss GA; Valentekovich RJ; Collins EJ; Garboczi DN; Lane WS; Schreiber SL; Wiley DC
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10945-8. PubMed ID: 8855288
[TBL] [Abstract][Full Text] [Related]
33. The South Amerindian allotype HLA-B*3909 has the largest known similarity in peptide specificity and common natural ligands with HLA-B27.
Yagüe J; Ramos M; Vázquez J; Marina A; Albar JP; López de Castro JA
Tissue Antigens; 1999 Mar; 53(3):227-36. PubMed ID: 10203015
[TBL] [Abstract][Full Text] [Related]
34. HLA class I-associated diseases with a suspected autoimmune etiology: HLA-B27 subtypes as a model system.
Uchanska-Ziegler B; Loll B; Fabian H; Hee CS; Saenger W; Ziegler A
Eur J Cell Biol; 2012 Apr; 91(4):274-86. PubMed ID: 21665321
[TBL] [Abstract][Full Text] [Related]
35. An HLA-B27 polymorphism (B*2710) that is critical for T-cell recognition has limited effects on peptide specificity.
García F; Rognan D; Lamas JR; Marina A; López de Castro JA
Tissue Antigens; 1998 Jan; 51(1):1-9. PubMed ID: 9459498
[TBL] [Abstract][Full Text] [Related]
36. Lack of carboxyl-terminal tyrosine distinguishes the B*2706-bound peptide repertoire from those of B*2704 and other HLA-B27 subtypes associated with ankylosing spondylitis.
García F; Marina A; López de Castro JA
Tissue Antigens; 1997 Mar; 49(3 Pt 1):215-21. PubMed ID: 9098927
[TBL] [Abstract][Full Text] [Related]
37. Pocket mutations of HLA-B27 show that anchor residues act cumulatively to stabilize peptide binding.
Parker KC; Biddison WE; Coligan JE
Biochemistry; 1994 Jun; 33(24):7736-43. PubMed ID: 8011638
[TBL] [Abstract][Full Text] [Related]
38. The pathogenesis of HLA-B27 associated arthritis: lessons from the B27 crystal.
Kellner H; Yu D
Clin Investig; 1994 Mar; 72(4):321-8. PubMed ID: 8043984
[TBL] [Abstract][Full Text] [Related]
39. Presentation of cytosolically stable peptides by HLA-B27 is not dependent on the canonic interactions of N-terminal basic residues in the A pocket.
Gómez P; Mavian C; Galocha B; García-Medel N; López de Castro JA
J Immunol; 2009 Jan; 182(1):446-55. PubMed ID: 19109176
[TBL] [Abstract][Full Text] [Related]
40. Molecular mechanism of the susceptibility difference between HLA-B*27:02/04/05 and HLA-B*27:06/09 to ankylosing spondylitis: substitution analysis, MD simulation, QSAR modelling, and in vitro assay.
Cheng X; Mei Y; Ji X; Xue Q; Chen D
SAR QSAR Environ Res; 2016 May; 27(5):409-25. PubMed ID: 27228481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
